文献速递肿瘤 PET/CT

68Ga-FAPI-04与18F-FDG PET/CT在局部晚期胃癌新辅助化疗病理反应早期预测中的价值

Value of 68Ga-FAPI-04 and 18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
PubMed 文献 · J Nucl Med · 2024-02-01

本前瞻性研究纳入28例局部晚期胃癌(LAGC)患者,在基线和1周期新辅助化疗(NAC)后行18F-FDG与68Ga-FAPI-04 PET/CT,评估PET参数预测病理反应的能力。主要病理反应者的68Ga-FAPI变化率显著低于次要病理反应者;68Ga-FAPI %SUVmax、%SUVpeak和%TBR可早期预测病理反应,预测准确率均为89.29%。

要点

  • 主要病理反应者的68Ga-FAPI变化率(%SUVmax、%SUVpeak、%TBR)显著低于次要病理反应者。
  • 68Ga-FAPI %SUVmax、%SUVpeak、%TBR预测病理反应的AUC分别为0.856、0.811、0.864,准确率均为89.29%。
  • 68Ga-FAPI变化率参数在早期预测NAC病理反应方面优于18F-FDG。

核心结论

  • 在这项初步研究中,68Ga-FAPI-04 PET变化率参数在早期预测LAGC对NAC的病理反应方面优于18F-FDG。
  • 68Ga-FAPI %SUVmax和%TBR可能是不同治疗方案间治疗反应的更好预测指标。
  • 这些发现可能有助于优化LAGC患者的治疗。

研究设计与样本

  • 前瞻性研究,纳入28例局部晚期胃癌(LAGC)患者。
  • 患者在基线和1周期新辅助化疗(NAC)后接受18F-FDG PET/CT和68Ga-FAPI-04 PET/CT。
  • 记录SUV、肿瘤/本底比值(TBR)及SUV和TBR的变化率。
  • 根据术后病理将患者分为主要病理反应者和次要病理反应者。

主要发现

  • 主要病理反应者的68Ga-FAPI变化率(%SUVmax、%SUVpeak、%TBR)显著低于次要病理反应者。
  • 68Ga-FAPI %SUVmax的AUC为0.856(P=0.009),%SUVpeak的AUC为0.811(P=0.022),%TBR的AUC为0.864(P=0.007),均为早期预测NAC病理反应的显著参数。
  • 68Ga-FAPI %SUVmax、%SUVpeak和%TBR的预测准确率均为89.29%,对应阈值分别为下降至至少52.43%、60.46%和52.96%。
  • 68Ga-FAPI %SUVmax和%TBR在不同治疗方案间显示显著差异。

关键数值与推荐

  • 主要病理反应者的68Ga-FAPI变化率显著低于次要病理反应者。
  • 68Ga-FAPI %SUVmax预测病理反应的AUC为0.856(P=0.009),阈值下降至至少52.43%。
  • 68Ga-FAPI %SUVpeak预测病理反应的AUC为0.811(P=0.022),阈值下降至至少60.46%。
  • 68Ga-FAPI %TBR预测病理反应的AUC为0.864(P=0.007),阈值下降至至少52.96%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文称本研究为初步研究(preliminary study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This prospective study investigated whether PET parameters from 18F-FDG and 68Ga-fibroblast activation protein inhibitor (FAPI)-04 PET/CT can predict a pathologic response to neoadjuvant chemotherapy (NAC) early in patients with locally advanced gastric cancer (LAGC). Methods: The study included 28 patients with LAGC who underwent 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT at baseline and after 1 cycle of NAC. PET parameters including SUV and tumor-to-background ratio (TBR), as well as the change rate of SUV and TBR, were recorded. Patients were classified as major or minor pathologic responders according to postoperative pathology findings. We compared the PET parameters between the 2 pathologic response groups and different treatment regimens and analyzed their predictive performance for tumor pathologic response. Results: Major pathologic responders had significantly lower 68Ga-FAPI change rates (percentage SUVmax [%SUVmax], percentage SUVpeak [%SUVpeak], and percentage TBR [%TBR]) than minor pathologic responders. Among the PET parameters, 68Ga-FAPI %SUVmax (area under the curve, 0.856; P = 0.009), %SUVpeak (area under the curve, 0.811; P = 0.022), and %TBR (area under the curve, 0.864; P = 0.007) were significant parameters for early prediction of pathologic response to NAC in LAGC; they had the same predictive accuracy of 89.29%, with the thresholds of decrease to at least 52.43%, 60.46%, and 52.96%, respectively. In addition, 68Ga-FAPI %SUVmax and %TBR showed significant differences between the different treatment regimens. Conclusion: In this preliminary study, 68Ga-FAPI-04 PET change rate parameters were preferable to 18F-FDG in predicting pathologic response to NAC at an early stage in LAGC. 68Ga-FAPI %SUVmax and %TBR may be better predictors of therapeutic response between different treatment regimens. These findings may help optimize the treatment for patients with LAGC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Miao Y, Feng R, Yu T, et al. Value of 68Ga-FAPI-04 and 18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer. J Nucl Med. 2024. PMID: 38164574. doi:10.2967/jnumed.123.266403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。